Investigation of the biological activity of the water-soluble C₆₀/poly-N-vinylpyrrolidone complex

Objectives. The study aimed to investigate the biological activity of the C₆₀/poly-N-vinylpyrrolidone (C₆₀/PVP) complex representing a water-soluble fullerene derivative. In vitro and in vivo techniques were used to analyze the effect of the C₆₀/PVP complex on the activity of lactate dehydrogenase (LDH) and evaluate changes in the biochemical parameters of blood serum when per os administered to mice.

Methods. In order to determine the activity of a commercial LDH preparation and study the kinetics of this process, the standard Warburg photometric method was used. To assess the effect of polyvinylpyrrolidone (PVP) and the C₆₀/PVP complex on some biochemical parameters in vivo, a study was conducted on two-month-old male white mongrel mice weighing 20 ± 3 g. Determination of biochemical parameters of blood serum was carried out using a semi-automatic biochemical analyzer according to standard methods.

Results. The effect of the C₆₀/PVP complex on LDH activity was studied along with changes in the biochemical parameters of mouse blood serum characterizing carbohydrate metabolism. As well as increasing the glucose and pyruvic acid content, the C₆₀/PVP complex was found to reduce lactate content and LDH activity in blood serum along with in vitro LDH activity according to the type of mixed inhibition.

Conclusions. The C₆₀/PVP complex and PVP were shown to exhibit biological activity in vitro and in vivo. The C₆₀/PVP complex, representing a mixed-type LDH inhibitor, was shown to inhibit LDH activity, as well as contributing to a decrease in lactate concentration and an increase in the concentration of pyruvic acid and glucose in blood serum when administered per os to mice. The inhibitory effect of PVP on LDH activity was revealed in both in vivo and in vitro investigations. In vivo, PVP contributes to a decrease in the concentration of lactate in the blood. The less pronounced effect of the C₆₀/PVP complex as compared to PVP alone may be due to the fact that C₆₀ molecules are “hidden” in cavities formed in PVP molecules.

1. Nielsen G., Roursgaard M., Jensen K., et al. In vivo Biology and Toxicology of Fullerenes and Their Derivatives. Basic Clin. Pharmacol. Toxicol. 2008;103(3):197–208. https://doi.org/10.1111/j.1742-7843.2008.00266.x

2. Shuster D.I., Wilson S.R., Shinazi R.F. Anti-human immunodeficiency virus activity and cytotoxicity of derivatized buckminsterfullerenes. Bioorg. Med. Chem. Lett. 1996;6(11):1253–1256. https://doi.org/10.1016/0960-894X(96)00210-7

3. Shinazi R.F., Sijbesma R., Sradanov G., et al. Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene Antimicrob. Agents Chemother.1993;37(8):1707–17110. https://doi.org/10.1128/AAC.37.8.1707

4. Bakry R., Vallant R., Najam-ul-Haq M., et al. Medicinal applications of fullerenes. Int. J. Nanomedicine. 2007;2(4):639–649.

5. Voroshilov E.A., Degtyarnikov V.P., Shuklina A.A.Prospects for the use of soft dosage forms with the addition of fullerene C60 in the treatment of inflammatory processes. In: Meditsinskaya pomoshch’ pri travmakh. Novoe v organizatsii i tekhnologiyakh. Perspektivy importozameshcheniya v Rossii (Medical care for injuries. New in organization and technology. Prospects for import substitution in Russia): Collection of abstracts of the Fifth Anniversary Congress with International Participation. St. Petersburg; 2020. Р. 63–64 (in Russ.).

6. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992;59(5):1609–1623. https://doi.org/10.1111/j.1471-4159.1992.tb10990.x

7. Krustic P.J., Wasserman E., Keizer P.N., et al. Radical reactions of C60. Science. 1991;254(5035):1183–1185. https://doi.org/10.1126/science.254.5035.1183

8. Aver’yanova M.O., Kurakin G.F., Lopina N.P., Bordina G.E. Prospects for the use of fullerenes and their derivatives as antioxidants. Modern Science. 2019;(6–3):11–14 (in Russ.).

9. Dugan L.L., et al. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat. Disord. 2001;7(3):243–246. https://doi.org/10.1016/S1353-8020(00)00064-X

10. Podolski I.Y., Podlubnaya Z.A., Kosenko E.A., Mugantseva E.A., Мakarova E.G. Effects of hydrated forms of C60 fullerene on amyloid β-peptide fibrillization in vitro and perfomance of the cognitive task. J. Nanosci. Nanotechnol. 2007;7(4–5):1479–1485. https://doi.org/10.1166/jnn.2007.330

11. Moussa F., Chretien P., Dubois P., Chuniaud L., Dessante M., Trivin F., Sizaret P.Y., Agafonov V., Ceolin R., Szwarc H., Greugny V., Fabre C., Rassat A. The Influence of C60 Powders on Cultured Human Leukocytes. Full. Sci. Technol. 2008;3(3):333–342. https://doi.org/10.1080/153638X9508543788

12. Moussa F., Trivin F., Ceolin R., Hadchouel M., Sizaret P.Y., Greugny V., Fabre C., Rassat A., Szwarc H. Early effects of C60 administration in Swiss mice: A preliminary account for in vivo C60 toxicity. Full. Sci. Technol. 1996;4(1):21–29. https://doi.org/10.1080/10641229608001534

13. Baati T., Bourasset F., Gharbi N., Njim L., Abderrabba M., Kerkeni A., Szwarc H., Moussa F. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. Biomaterials. 2012;33(19):4936–4946. https://doi.org/10.1016/j.biomaterials.2012.03.036

14. Hendrickson O., Fedyunina N., Zherdev A., Solopova O., Sveshnikov P. Dzantiev B. Production of monoclonal antibodies against fullerene C60 and development of a fullerene enzyme immunoassay. Analyst. 2012;137(1):98–105. https://doi.org/10.1039/C1AN15745K

15. Da Ros T., Spalluto G., Prato M. Biological Applications of Fullerene Derivatives: A Brief Overview. Croatica Chemica Acta. 2001;74(4):743–755.

16. Belgorodsky B., Fadeev L., Ittah V., Benyamini H., Zelner S., Huppert D., Kotlyar A. B., Gozin M. Formation and characterization of stable human serum albumin-trismalonic acid [C60]fullerene complex. Bioconjug. Chem. 2005;16(5):1058–1062. https://doi.org/10.1021/bc050103c

17. Dumpis M.A., Nikolaev D.N., Litasova E.V., Il’in V.V., Brusina M.A., Piotrovskii P.B. Biological activity of fullerenes – realities and prospects. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii (Reviews on Clinical Pharmacology and Drug Therapy). 2018;16(7):4–20 (in Russ.). https://doi.org/10.17816/RCF1614-20

18. Benyamini H., Shulman-Peleg A., Wolfson H.J., Belgorodsky B., Fadeev L., Gozin M. Interaction of C60-fullerene and carboxyfullerene with proteins: docking and binding site alignment. Bioconjug. Chem. 2006;17(2):378–386. https://doi.org/10.1021/bc050299g

19. Gharbi N., Pressac M., Hadchouel M., Szwarc H., Wilson S.R., Moussa F. [60] Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5(12):2578–2585. https://doi.org/10.1021/nl051866b

20. Xiao L., Takada H., Gan X.H., et al. The water-soluble fullerene derivative ‘Radical Sponge®’ exerts cytoprotective action against UVA irradiation but not visible-light-catalyzed cytotoxicity in human skin keratinocytes. Bioorg. Med. Chem. Lett. 2006;16(6):1590–1595. https://doi.org/10.1016/j.bmcl.2005.12.011

21. Barzegar A., Naghizadeh E., Zakariazaden M., Azamat J. Molecular dynamics simulation study of the HIV-1 protease inhibit ion using fullerene and new fullerene derivatives of carbon nanostructures. Mini Rev. Med. Chem. 2017;17(7):633–647.

22. Martinez Z.S., Castro E., Seong C.-S., Ceron M.R., Echegoyen L., Llano M. Fullerene derivatives strongly inhibit HIV-1 replication by affecting virus maturation without impairing protease activity. Antimicrob. Agents Chemother. 2016;60(10):5731–5741. https://doi.org/10.1128/AAC.00341-16

23. Gun’kin I.F., Tseluikin V.N., Loginova N.Yu. Synthesis and properties of water-soluble derivatives of fullerene C60. Russ. J. Appl. Chem. 2006;79(6):1001–1004. https://doi.org/10.1134/S1070427206060243 [Original Russian Text: Gun’kin I.F., Tseluikin V.N., Loginova N.Yu. Synthesis and properties of water-soluble derivatives of fullerene C60. Zhurnal Prikladnoi Khimii. 2006;79(6):1011–1013 (in Russ.).]

24. Karkishchenko N.N., Grachev S.V. (Eds.). Rukovodstvo po laboratornym zhivotnym i al’ternativnym modelyam v biomeditsinskikh issledovaniyakh (The Guide to Laboratory Animals and Alternative Models in Biomedical Research). Moscow: Profil’-2S; 2010. 358 p. (in Russ.).

25. Karpishchenko A.I. Meditsinskie laboratornye tekhnologii (Medical Laboratory Technologies). St. Petersburg: Intermedika; 1999. 656 p. (in Russ.).